Hansoh is a research and development-driven pharmaceutical company holding a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. The company is building a sustainable profit engine through overseas out-licensing deals, including a blockbuster deal with MSD for an oral small molecule GLP-1R agonist.
Cyborg Score Rationale
Sales of innovative drugs saw strong growth of 28.2% YoY, with FY24 revenue of RMB12.26bn and attributable net income of RMB4.37bn. 25 analysts recommend buying the stock while only 1 suggests selling. Strong fundamentals offset growth concerns related to pricing pressures in China's pharmaceutical market.
Top Insights
Innovative drug sales grew 28.2% YoY in FY24, demonstrating robust commercialization of R&D pipeline
Strategic out-licensing deals with GSK and MSD unlock overseas value from proprietary compounds
China's largest psychotropic drug producer with diversified therapeutic portfolio reduces single-area risk
Founder family owns 66% of company, ensuring aligned long-term strategic incentives
Named Competitors
Shanghai Fosun Pharmaceutical — Diversified Chinese pharma with generic and specialty drugs
China Traditional Chinese Medicine Holdings — Chinese traditional medicine and modern pharma products
Sihuan Pharmaceutical — Specialty pharma focused on CNS and oncology drugs
Recent Developments
(December 2025) UBS and HSBC maintained Buy ratings; 25 of 26 analyst recommendations are Buy or equivalent
(December 2025) Company advanced with new drug inclusions in 2025 NRDL reimbursement list
(March 2025) Beat earnings expectations with EPS of HK$0.306 vs consensus HK$0.251
Open the full interactive Hansoh Pharmaceutical Group Company Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.